首页> 外文期刊>Journal of Clinical and Diagnostic Research >Beta-lactamase Profile and Biofilm Production of Pseudomonas aeruginosa Isolated from a Tertiary Care Hospital in Kolkata, India
【24h】

Beta-lactamase Profile and Biofilm Production of Pseudomonas aeruginosa Isolated from a Tertiary Care Hospital in Kolkata, India

机译:β-内酰胺酶概况和生物膜生成的假单胞菌铜绿假单胞菌,从印度加尔各答的三级护理医院分离出来

获取原文
获取外文期刊封面目录资料

摘要

Nosocomial infections caused by Multidrug Resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) have become a major clinical and public health concern. Moreover, the biofilm production protects the bacteria from antibiotics and thereby makes the drugs ineffective.Aim: To find out the β-lactamases profile of antimicrobial resistance and biofilm production of P. aeruginosa isolated from different clinical specimens of patients attending a tertiary care hospital of Kolkata, West Bengal, India.Materials and Methods: A total of 394 consecutive, non-duplicate isolates of P. aeruginosa were identified from 3559 Gram negative bacilli over a period of two years from July 2016 to June 2018. Identification of the isolates and antibiotic sensitivity testing was performed by using automated method and interpreted. Extended Spectrum β-Lactamases (ESBLs), Amp-C β-lactamase (AmpC) and Metallo-β-Lactamases (MBLs) were phenotypically detected by disk synergy test and MBL-encoding genes were detected by multiplex Polymerase Chain Reaction (PCR). Biofilm production was done by tissue culture plate assay. Laboratory data and test results were statistically analysed in counts and percentages using MS Excel 2010 version.Results: Out of 394 strains of P. aeruginosa 288 (73.10%) were isolated from male patients whereas 106 (26.90%) were isolated from female patients. Maximum number of cases (67.26%) were from adult populations. The resistance pattern showed 72.33% resistance to ticarcillin-clavulanic acid followed by ciprofloxacin (53.80%), levofloxacin (50.25%), gentamicin (51.52%), ceftazidime (CAZ) (45.93%), cefoperazone-sulbactam (40.1%), aztreonam (34.77%), imipenem (33.5%), piperacillin/tazobactum (30.96%) and Meropenem (MRP) (29.18%). Out of 394 Pseudomonas spp isolates, 204 (51.77%) were MDR. Overall, ESBLs, AmpC and carbapenemase (MBL) production was detected in 145 (36.80%), 51 (12.94%) and 49 (12.43%) isolates by phenotypic methods. By genotypic method 53.34% were carbapenemase producing and bla _(NDM-1) (68.75%) was the most prevalent carbapenemase gene detected followed by bla _(VIM) (18.75%) and co-production of bla _(NDM-1)+ bla _(VIM) was 12.5%. Biofilm production was observed in 158 (40.10%) isolates.Conclusion: Early detection of these β-lactamases production is crucial not only for epidemiological study and effective infection control practices to limit the spread of infection but also for planning appropriate therapy according to the resistance mechanisms of the MDR strains.
机译:多药抗性引起的医院感染(MDR)假单胞菌铜绿假单胞菌(P. Aerginosa)已成为一个主要的临床和公共卫生问题。此外,生物膜生产可保护细菌免受抗生素,从而使药物无效。目的:找出抗微生物抗性和生物膜的β-内酰胺酶的曲线型 p。从出席加尔各答,西孟加拉邦,西孟加拉邦的患者的不同临床标本中孤立的铜绿假单胞菌,西孟加拉邦,印度。材料和方法:总共394个连续的,不一致的 p的分离物。从2016年7月至2018年6月,从3559克阴性Bacilli鉴定了3559克阴性杆菌。通过使用自动化方法和解释,进行分离物和抗生素敏感性测试的鉴定。扩展光谱β-内酰胺酶(ESBLS),AMP-Cβ-内酰胺酶(AMPC)和金属-β-内酰胺(MBLS)通过磁盘协同测试进行了表型检测,通过多重聚合酶链反应(PCR)检测MBL编码基因。生物膜生产由组织培养板测定进行。使用MS Excel 2010版本的计数和百分比进行统计分析实验室数据和测试结果。结果:在394个菌株中 p。铜绿假单胞菌288(73.10%)与男性患者分离,而106(26.90%)与女性患者分离。最大案件(67.26%)来自成人人群。抗性图案显示对蒂卡西林 - 克拉维酸的抗性72.33%,然后是环丙沙星(53.80%),左氧氟沙星(50.25%),庆大霉素(51.52%),头孢他啶(Cez)(45.93%),Cefoperazone-sulbactam(40.1%),阿兹特康(34.77%),Imipenem(33.5%),piperacillin / tazobactum(30.96%)和梅洛涅姆(MRP)(29.18%)。在394中 Pseudomonas SPP分离物,204(51.77%)是MDR。总体而言,通过表型方法在145(36.80%),51(12.94%)和49(12.43%)分离物中检测到ESBLS,AMPC和碳碱蛋白酶(MBL)产生。通过基因型方法53.34%是碳结氨酸酶产生,并且 BLA _(NDM-1)(68.75%)是检测到最普遍的碳碱酶基因,然后是 BLA _(Vim)(18.75%)和共同产生< I> BLA _(NDM-1)+ BLA _(VIM)为12.5%。在158(40.10%)分离株中观察到生物膜生产。结论:这些β-乳酰胺酶的早期检测不仅对流行病学研究和有效的感染控制实践来说至关重要,以限制感染的传播,还要根据规划适当的治疗对MDR菌株的电阻机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号